In order to replace SOC, Imugene would have to run Phase 3 trials... Where 1st arm of people get first line - Imugene Virus vs 2nd arm of people get First line - SOC. So we have a direct comparison of Imugene vs SOC and show a signficantly greater efficacy.
Oncology trials can replace the standard of care by demonstrating through rigorous research that a new treatment is significantly more effective or has a better safety profile compared to the currently accepted standard treatment, usually in Phase III clinical trials, which then leads to regulatory approval and widespread adoption of the new treatment as the new standard of care for that specific cancer type. The primary goal of a Phase III oncology trial is to compare the new experimental treatment to the current standard of care, allowing researchers to assess if the new treatment offers superior efficacy or tolerability.
None of the current trials are setup this way.
IMU Price at posting:
3.9¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)